- Home
- IFBD vs TOVX Comparison
IFBD vs TOVX Comparison
Compare IFBD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFBD | TOVX |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 10.1M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | IFBD | TOVX |
|---|---|---|
| Price | $0.99 | $0.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 4.5K | ★ 427.7K |
| Earning Date | 05-01-2023 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.16 |
| 52 Week High | $2.18 | $0.86 |
Technical Indicators
Market Signals| Indicator | IFBD | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 42.01 |
| Support Level | $0.86 | $0.22 |
| Resistance Level | $1.09 | $0.26 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 60.00 | 20.90 |
Price Performance
Historical ComparisonAbout IFBD Infobird Co. Ltd
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.